
VentriPoint Diagnostics Investor Relations Material
Latest events

AGM 2024
VentriPoint Diagnostics

Q1 2025
29 May, 2025

Q4 2024
29 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from VentriPoint Diagnostics Ltd
Access all reports
VentriPoint Diagnostics Ltd. is a Canadian medical device company specializing in the development and commercialization of innovative cardiac diagnostic tools. Their flagship product, the VentriPoint Medical System (VMS+), represents a significant advancement in heart imaging technology. VMS+ is designed to provide a detailed 3D visualization of the heart's structure and function without the need for magnetic resonance imaging (MRI). This system enhances ultrasound capabilities, offering a cost-effective, fast, and accurate diagnostic solution that enables the analysis of all four heart chambers, with a particular focus on the right ventricle, which is challenging to image using conventional methods. The technology's proprietary Knowledge Based Reconstruction (KBR) technology facilitates the creation of 3D heart models and calculates volumes and ejection fractions with accuracy comparable to MRI standards. The company is headquartered in Toronto, Canada, and its shares are listed on the TSX.
Latest articles
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
Ticker symbol
VPT
Country
🇨🇦 Canada